Logo Logo
Switch Language to German

Gossrau, Gudrun; Foerderreuther, Stefanie; Ruscheweyh, Ruth; Ruschil, Victoria; Sprenger, Till; Lewis, David; Kamm, Katharina; Freilinger, Tobias; Neeb, Lars; Malzacher, Volker; Meier, Uwe; Gehring, Klaus; Kraya, Torsten; Dresler, Thomas; Schankin, Christoph J.; Gantenbein, Andreas R.; Broessner, Gregor; Zebenholzer, Karin; Diener, Hans-Christoph; Gaul, Charly and Juergens, Tim P. (2022): Konsensusstatement der Migräne- und Kopfschmerzgesellschaften (DMKG, ÖKSG & SKG) zur Therapiedauer der medikamentösen Migräneprophylaxe. In: Schmerz, Vol. 37, No. 1: pp. 5-16

Full text not available from 'Open Access LMU'.


Migraine is the most common neurological disorder and can be associated with a high degree of disability. In addition to non-pharmacological approaches to reduce migraine frequency, pharmacological migraine preventatives are available. Evidence-based guidelines from the German Migraine and Headache Society (DMKG), and German Society for Neurology (DGN), Austrian Headache Society (oKSG), and Swiss Headache Society (SKG) are available for indication and application. For therapy-relevant questions such as the duration of a pharmacological migraine prevention, no conclusions can be drawn from currently available study data. The aim of this review is to present a therapy consensus statement that integrates the current data situation and, where data are lacking, expert opinions. The resulting current recommendations on the duration of therapy for pharmacological migraine prophylaxis are shown here.

Actions (login required)

View Item View Item